Suven Life Sciences Ltd

As of 24-Nov, Suven Life Sciences Ltd witnessed a notable decline in its share price, falling by 3.9% to close at ₹168.75. This drop reflects mounting concerns over the company’s deteriorating financial health despite its strong historical returns and increasing institutional interest.

As of 18-Nov, Suven Life Sciences Ltd's stock price is Rs 178.50, down 1.3%, and has declined 4.21% over the last two days. Despite a strong year-to-date return, the company faces ongoing operational challenges and negative cash flow, contributing to a bearish trend and cautious investor sentiment.

Suven Life Sciences has experienced a significant decline in financial performance, with net sales dropping from 285.67 crore in March 2019 to 6.66 crore in March 2025, and increasing losses leading to a net profit of -160.75 crore in March 2025. The company faces ongoing operational challenges, reflected in negative cash flow and reduced asset values.

Suven Life Sciences' latest Q2 FY26 results are concerning, showing a net loss of ₹51.52 crores despite an 85.15% year-on-year sales growth from a low base, indicating significant operational challenges and financial instability. The company's unsustainable cost structure and persistent losses raise serious questions about its long-term viability.

As of 07-Nov, Suven Life Sciences Ltd's stock price is Rs 189.50, down 1.43%, and has fallen for three consecutive days, totaling a 7.38% decline. Despite a strong year-to-date return, recent negative financial results and a bearish trend have raised investor concerns.

Suven Life Sciences will announce its results on 11 November 2025.

As of 29-Sep, Suven Life Sciences Ltd's stock price is at 201.75, down 3.63% and has dropped 13.13% over the last five days. Despite a strong year-to-date performance, the company faces significant challenges, including operating losses and a declining profit trend, contributing to its current stock decline.

Suven Life Sciences Ltd, a small-cap healthcare company, reached its upper circuit limit today, achieving a significant intraday high. The stock exhibited strong trading volume and consecutive gains over the past two days, reflecting its robust market position and resilience despite broader market declines.

Suven Life Sciences Ltd is experiencing notable buying activity, with the stock rising significantly today, while the Sensex has declined. Over the past week, Suven has shown strong performance, and its year-over-year growth contrasts with the Sensex's decline, indicating a robust upward trend in the stock.

As of 18-Sep, Suven Life Sciences Ltd's stock price is at 220.20, down 2.91% and has underperformed the sector and market recently, with negative returns over the past week and month. The company's weak fundamentals and declining profits have contributed to a lack of investor confidence, leading to its current downward trend.

As of 10-Sep, Suven Life Sciences Ltd's stock price is declining at 220.00, down 1.08%, with a total drop of 5.94% over two days. Despite a strong year-to-date performance, the company faces significant challenges, including operating losses and negative EBITDA, leading to weak long-term fundamentals.

Suven Life Sciences Ltd is experiencing significant selling pressure, with the stock declining sharply today, contrasting with the overall market's gains. Despite a positive weekly performance, the stock has seen a notable monthly decline. Current trends suggest a shift in investor sentiment, impacting its market performance.

Suven Life Sciences Ltd experienced significant trading activity, reaching its upper circuit limit with a high of Rs 233.36. The stock saw a total traded volume of approximately 0.54504 lakh shares and a turnover of Rs 1.25 crore, indicating the volatility typical of small-cap stocks in the healthcare sector.

Suven Life Sciences Ltd is experiencing notable buying activity, with a significant rise in stock performance over the past week. The stock has shown strong long-term growth, particularly in the healthcare services sector, despite a recent monthly decline. Its current price exceeds multiple moving averages, indicating a positive trend.

Suven Life Sciences Ltd, a small-cap in the Healthcare Services sector, reached its upper circuit limit today, with significant trading activity. The stock's performance indicates a positive trend, outperforming its sector and showing strong trading dynamics, while trading above several moving averages.